Mr•K
22.1K posts

Mr•K
@Mr_K2015
Must have been stupid enough to start trading, and determined enough to make it work.


$LLY may still be better positioned than $NVO for long term portfolio outperformance, according to The Motley Fool, but the debate increasingly comes down to leadership versus valuation. The bullish case for Lilly: • ~60% U.S. obesity market share • stronger recent revenue momentum • superior weight loss data from tirzepatide vs semaglutide • oral Foundayo now launching • manufacturing scale has improved access The bullish case for Novo: • materially lower valuation • early uptake in oral Wegovy • a pill format may attract patients who do not want injections The key investor question is whether Novo’s lower multiple can offset continued share losses to Lilly. Link to article: fool.com/investing/2026… #stocks #Investing

@MarkWal17068493 Pubx are the open web and on fire right now due to their amazing product. We are CTV. An agentic dream team











